<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00225784</url>
  </required_header>
  <id_info>
    <org_study_id>DMS 0432</org_study_id>
    <nct_id>NCT00225784</nct_id>
  </id_info>
  <brief_title>Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial of Cetuximab, Radiotherapy and Twice Weekly Gemcitabine in Patients With Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to establish the safety and efficacy of a combination of Erbitux
      (cetuximab)/Gemzar (gemcitabine)/radiation in patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study treatment for this protocol is

        -  Loading dose of Cetuximab 400 mg/m2

        -  Weekly Cetuximab 250 mg/m2

        -  Bi-weekly Gemcitabine 50 mg/m2

        -  Daily Radiation for 28 fractions

        -  CT scan four weeks after completion of treatment

        -  Evaluation by surgeon for resectability
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response of Tumor by RECIST 1.0 Criteria</measure>
    <time_frame>one month post-therapy</time_frame>
    <description>Per RECIST Criteria (v. 1.0) and assessed by CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in sum of the longest diameter (SLD)of target lesions at baseline; Progressive Disease (PD), &gt;=20% increase in the SLD of target lesions at baseline; Stable Disease (SD), Neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Assessed for Adverse Events</measure>
    <time_frame>Participants were followed during treatment and for 30 days after completion of treatment</time_frame>
    <description>Adverse events assessed using Common Terminology Criteria for Adverse Events version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Determined to be Resectable (Eligible for Surgery)After Completion of Therapy</measure>
    <time_frame>1 month after completion of treatment</time_frame>
    <description>Tumor resectability is based on CT scan and as defined by the American Hepato-Pancreato-Biliary Association Convened Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer (Callery MP, et al. Ann Surg Oncol 2009; 16:1727-1733): no evidence of superior mesenteric vein (SMV) or portal vein (PV)abutment, distortion, tumor thrombus, or venous encasement, and clear fat planes around celiac axis (CA), hepatic artery (HA), and superior mesenteric artery (SMA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of Epidermal Growth Factor Receptor (EGFR) Status in Response to Treatment.</measure>
    <time_frame>One month post-therapy</time_frame>
    <description>Tumor was assessed for EGFR status by immunohistochemistry. EGFR positive and EGRF negative tumor types were evaluated and compared for response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival After Therapy</measure>
    <time_frame>Five years post treatment</time_frame>
    <description>Time to disease progression after therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Length of Survival After Therapy</measure>
    <time_frame>Five years post treatment</time_frame>
    <description>Length of survival after therapy in all participants enrolled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of Failure After Therapy</measure>
    <time_frame>Five years post treatment</time_frame>
    <description>Local recurrence, distant recurrence, or both.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab, Gemcitabine, RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab/Gemcitabine</intervention_name>
    <description>Once weekly Cetuximab, twice weekly Gemcitabine for six weeks</description>
    <arm_group_label>Cetuximab, Gemcitabine, RT</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Daily radiotherapy for 28 days</description>
    <arm_group_label>Cetuximab, Gemcitabine, RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic proof of pancreatic adenocarcinoma

          -  Clinical stage I, II, or III disease

          -  Radiographically measurable disease

          -  Tumor tissue for epidermal growth factor receptor (EGFR) status by
             immunohistochemistry

          -  Signed protocol consent

          -  Karnofsky performance status of at least 70%

          -  Age &gt; or = to 18 years

          -  Patients must either not be of child bearing potential or have a negative pregnancy
             test within 72 hours of treatment.

          -  Absolute neutrophil count (ANC) &gt; 1500; platelets &gt; 100,000/ul.

          -  Creatinine &lt; 1.5 x upper limit of normal (ULN)

          -  Bilirubin &lt; 1.5 x ULN; AST &lt; 2.5 x ULN.

        Exclusion Criteria:

          -  Acute hepatitis or known HIV

          -  Active or uncontrolled infection

          -  Significant history of cardiac disease

          -  Prior therapy which affects or targets the EGF pathway

          -  Prior severe infusion reaction to a monoclonal antibody

          -  Any concurrent chemotherapy not indicated in the study protocol or any other
             investigational agents

          -  Any previous chemotherapy or abdominal or pelvic radiotherapy

          -  No prior malignancy is allowed except for adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer, or malignancy for which the patient has
             been disease free for five years.

          -  Any severe pre-existing medical or psychiatric condition, which, in the opinion of the
             attending physician, will interfere with safe and appropriate treatment and follow-up
             on study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Marc Pipas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2005</study_first_submitted>
  <study_first_submitted_qc>September 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <results_first_submitted>August 22, 2012</results_first_submitted>
  <results_first_submitted_qc>April 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2013</results_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage I, II, III pancreatic adenocarcinoma</keyword>
  <keyword>Radiographically measurable disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single-institution study of weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy in patients with pancreatic ductal adenocarcinoma conducted at Dartmouth-Hitchcock.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab, Gemcitabine, Radiotherapy</title>
          <description>Weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab/Gemcitabine/Radiotherapy</title>
          <description>weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" lower_limit="39" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.1" lower_limit="67" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response of Tumor by RECIST 1.0 Criteria</title>
        <description>Per RECIST Criteria (v. 1.0) and assessed by CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in sum of the longest diameter (SLD)of target lesions at baseline; Progressive Disease (PD), &gt;=20% increase in the SLD of target lesions at baseline; Stable Disease (SD), Neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD.</description>
        <time_frame>one month post-therapy</time_frame>
        <population>Completion of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Gemcitabine, Radiotherapy</title>
            <description>Weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response of Tumor by RECIST 1.0 Criteria</title>
          <description>Per RECIST Criteria (v. 1.0) and assessed by CT scan: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in sum of the longest diameter (SLD)of target lesions at baseline; Progressive Disease (PD), &gt;=20% increase in the SLD of target lesions at baseline; Stable Disease (SD), Neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD.</description>
          <population>Completion of treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Assessed for Adverse Events</title>
        <description>Adverse events assessed using Common Terminology Criteria for Adverse Events version 3.0</description>
        <time_frame>Participants were followed during treatment and for 30 days after completion of treatment</time_frame>
        <population>All participants were evaluated for toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Gemcitabine, Radiotherapy</title>
            <description>Weekly cetuximab twice-weekly gemcitabine plus intensity modulated radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Assessed for Adverse Events</title>
          <description>Adverse events assessed using Common Terminology Criteria for Adverse Events version 3.0</description>
          <population>All participants were evaluated for toxicity.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Determined to be Resectable (Eligible for Surgery)After Completion of Therapy</title>
        <description>Tumor resectability is based on CT scan and as defined by the American Hepato-Pancreato-Biliary Association Convened Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer (Callery MP, et al. Ann Surg Oncol 2009; 16:1727-1733): no evidence of superior mesenteric vein (SMV) or portal vein (PV)abutment, distortion, tumor thrombus, or venous encasement, and clear fat planes around celiac axis (CA), hepatic artery (HA), and superior mesenteric artery (SMA).</description>
        <time_frame>1 month after completion of treatment</time_frame>
        <population>Surviving participants who completed therapy and were determined to be resectable.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Gemcitabine, Radiotherapy</title>
            <description>Weekly cetuximab twice-weekly gemcitabine plus intensity modulated radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Determined to be Resectable (Eligible for Surgery)After Completion of Therapy</title>
          <description>Tumor resectability is based on CT scan and as defined by the American Hepato-Pancreato-Biliary Association Convened Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer (Callery MP, et al. Ann Surg Oncol 2009; 16:1727-1733): no evidence of superior mesenteric vein (SMV) or portal vein (PV)abutment, distortion, tumor thrombus, or venous encasement, and clear fat planes around celiac axis (CA), hepatic artery (HA), and superior mesenteric artery (SMA).</description>
          <population>Surviving participants who completed therapy and were determined to be resectable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Role of Epidermal Growth Factor Receptor (EGFR) Status in Response to Treatment.</title>
        <description>Tumor was assessed for EGFR status by immunohistochemistry. EGFR positive and EGRF negative tumor types were evaluated and compared for response to treatment.</description>
        <time_frame>One month post-therapy</time_frame>
        <population>All EGFR (-) subjects who completed therapy were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Gemcitabine, Radiotherapy in EGFR (-) Tumors</title>
            <description>Percentage of response to weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy in patients with EGFR negative tumors.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab, Gemcitabine, Radiotherapy in EGFR (+) Tumors</title>
            <description>Percentage of response to weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy in patients with EGFR positive tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Role of Epidermal Growth Factor Receptor (EGFR) Status in Response to Treatment.</title>
          <description>Tumor was assessed for EGFR status by immunohistochemistry. EGFR positive and EGRF negative tumor types were evaluated and compared for response to treatment.</description>
          <population>All EGFR (-) subjects who completed therapy were evaluated.</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Free Survival After Therapy</title>
        <description>Time to disease progression after therapy.</description>
        <time_frame>Five years post treatment</time_frame>
        <population>All evaluable participants who completed treatment, and had confirmed progression of disease.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Gemcitabine, Radiotherapy</title>
            <description>Weekly cetuximab twice-weekly gemcitabine plus intensity modulated radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Survival After Therapy</title>
          <description>Time to disease progression after therapy.</description>
          <population>All evaluable participants who completed treatment, and had confirmed progression of disease.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="2">Partipants did not all reach endpoint.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Length of Survival After Therapy</title>
        <description>Length of survival after therapy in all participants enrolled.</description>
        <time_frame>Five years post treatment</time_frame>
        <population>All participants enrolled regardless of evaluability for primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Gemcitabine, Radiotherapy</title>
            <description>Weekly cetuximab twice-weekly gemcitabine plus intensity modulated radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Length of Survival After Therapy</title>
          <description>Length of survival after therapy in all participants enrolled.</description>
          <population>All participants enrolled regardless of evaluability for primary outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="2">Not all participants evaluated reached end point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pattern of Failure After Therapy</title>
        <description>Local recurrence, distant recurrence, or both.</description>
        <time_frame>Five years post treatment</time_frame>
        <population>All participants who completed treatment and underwent resection</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Gemcitabine, Radiotherapy</title>
            <description>Weekly cetuximab twice-weekly gemcitabine plus intensity modulated radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Pattern of Failure After Therapy</title>
          <description>Local recurrence, distant recurrence, or both.</description>
          <population>All participants who completed treatment and underwent resection</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of participants with local recurrence only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of ppts. with local and distant recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of ppts. with distant disease recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of ppts. without recurrence or unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab/Gemcitabine/Radiotherapy</title>
          <description>weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Of the 22 patients experiencing Grade 3 neutropenia, only one developed neutropenic fever requiring hospitalization. The other 21 were managed in an outpatient setting.</description>
                <counts group_id="E1" events="34" subjects_affected="22" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder - stent obstruction</sub_title>
                <description>Stent obstruction is common in patients with pancreatic cancer.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gastritis/GI Bleed</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - gouty arthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hematoma subdural</sub_title>
                <description>This was related to a traumatic event, not to treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxtic reaction to erbitux</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study suffers limitations common to single institution trials, namely small patient numbers and selection bias. Our cohort of subjects is too small to adequately assess the effect of tumor EGFR and KRAS status on outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>J. Marc Pipas, MD</name_or_title>
      <organization>Dartmouth-Hitchcock</organization>
      <phone>603-650-9474</phone>
      <email>J.Marc.Pipas@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

